21 research outputs found
SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150
SPROUTY-2 (SPRY2) is a modulator of tyrosine kinase receptor signaling with
receptor- and cell type-dependent inhibitory or enhancing effects. Studies on the action
of SPRY2 in major cancers are conflicting and its role remains unclear. Here we have
dissected SPRY2 action in human colon cancer. Global transcriptomic analyses show
that SPRY2 downregulates genes encoding tight junction proteins such as claudin-7 and
occludin and other cell-to-cell and cell-to-matrix adhesion molecules in human SW480-
ADH colon carcinoma cells. Moreover, SPRY2 represses LLGLL2/HUGL2,
PATJ1/INADL and ST14, main regulators of the polarized epithelial phenotype, and
ESRP1, an epithelial-to-mesenchymal transition (EMT) inhibitor. A key action of
SPRY2 is the upregulation of the major EMT inducer ZEB1, as these effects are
reversed by ZEB1 knock-down by means of RNA interference. Consistently, we found
an inverse correlation between the expression level of claudin-7 and those of SPRY2
and ZEB1 in human colon tumors. Mechanistically, ZEB1 upregulation by SPRY2
results from the combined induction of ETS1 transcription factor and the repression of
microRNAs (miR-200 family, miR-150) that target ZEB1 RNA. Moreover, SPRY2
increased AKT activation by epidermal growth factor (EGF) whereas AKT and also Src
inhibition reduced the induction of ZEB1. Altogether, these data suggest that AKT and
Src are implicated in SPRY2 action. Collectively, these results show a tumorigenic role
of SPRY2 in colon cancer that is based on the dysregulation of tight junction and
epithelial polarity master genes via upregulation of ZEB1. The dissection of the
mechanism of action of SPRY2 in colon cancer cells is important to understand the
upregulation of this gene in a subset of patients with this neoplasia that have poor
prognosis.This study was supported by the Ministerio de
Economía y Competitividad of Spain and Fondo Europeo de Desarrollo Regional
(FEDER) (grant SAF2013-43468-R to A.M., SAF2011-29530 to F.X.R.); FEDERInstituto
de Salud Carlos III (RD12/0036/0021 to A.M. and J.M.R., RD12/0036/0034 to
F.X.R., RD12/0036/0016 to M.S., RD12/0036/0012 to H.G.P., RD06/0020/0003,
PS09/00562 and PI13/00703 to J.M.R.); Comunidad de Madrid (S2010/BMD-2344
Colomics2 to A.M.); Fundación Científica de la Asociación Española contra el Cáncer
(to J.M.R.); U.S. Department of Defense (CA093471 and CA110602 to E.H.); National
Institutes of Health/National Cancer Institute (1R01CA155234-01 to E.H.); National
Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin
Diseases (1R21AR062239-01 to E.H.); and the Melanoma Research Alliance (to E. H.)
Preclinical Models of Brain Metastasis
Research at the Brain Metastasis Group is supported by MINECO grants MINECO-Retos SAF2017-89643-R (M.V.), Bristol-Myers Squibb- Melanoma Research Alliance Young Investigator Award 2017 (498103) (M.V.), Beug Foundation’s Prize for Metastasis Research 2017 (M.V.), Fundación Ramón
Areces (CIVP19S8163) (M.V.), Worldwide Cancer Research (19-0177) (M.V.), H2020-FETOPEN (828972)N
InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma
We are conducting a multicenter study to identify classifiers predictive of disease-specific
survival in patients with primary melanomas. Here we delineate the unique aspects, challenges, and best practices for optimizing a study of generally small-sized pigmented tumor
samples including primary melanomas of at least 1.05mm from AJTCC TNM stage IIA-IIID
patients. We also evaluated tissue-derived predictors of extracted nucleic acids’ quality and
success in downstream testing. This ongoing study will target 1,000 melanomas within the
international InterMEL consortium.Medicin
InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma
INTRODUCTION: We are conducting a multicenter study to identify classifiers predictive of disease-specific survival in patients with primary melanomas. Here we delineate the unique aspects, challenges, and best practices for optimizing a study of generally small-sized pigmented tumor samples including primary melanomas of at least 1.05mm from AJTCC TNM stage IIA-IIID patients. We also evaluated tissue-derived predictors of extracted nucleic acids' quality and success in downstream testing. This ongoing study will target 1,000 melanomas within the international InterMEL consortium. METHODS: Following a pre-established protocol, participating centers ship formalin-fixed paraffin embedded (FFPE) tissue sections to Memorial Sloan Kettering Cancer Center for the centralized handling, dermatopathology review and histology-guided coextraction of RNA and DNA. Samples are distributed for evaluation of somatic mutations using next gen sequencing (NGS) with the MSK-IMPACTTM assay, methylation-profiling (Infinium MethylationEPIC arrays), and miRNA expression (Nanostring nCounter Human v3 miRNA Expression Assay). RESULTS: Sufficient material was obtained for screening of miRNA expression in 683/685 (99%) eligible melanomas, methylation in 467 (68%), and somatic mutations in 560 (82%). In 446/685 (65%) cases, aliquots of RNA/DNA were sufficient for testing with all three platforms. Among samples evaluated by the time of this analysis, the mean NGS coverage was 249x, 59 (18.6%) samples had coverage below 100x, and 41/414 (10%) failed methylation QC due to low intensity probes or insufficient Meta-Mixed Interquartile (BMIQ)- and single sample (ss)- Noob normalizations. Six of 683 RNAs (1%) failed Nanostring QC due to the low proportion of probes above the minimum threshold. Age of the FFPE tissue blocks (p<0.001) and time elapsed from sectioning to co-extraction (p = 0.002) were associated with methylation screening failures. Melanin reduced the ability to amplify fragments of 200bp or greater (absent/lightly pigmented vs heavily pigmented, p<0.003). Conversely, heavily pigmented tumors rendered greater amounts of RNA (p<0.001), and of RNA above 200 nucleotides (p<0.001). CONCLUSION: Our experience with many archival tissues demonstrates that with careful management of tissue processing and quality control it is possible to conduct multi-omic studies in a complex multi-institutional setting for investigations involving minute quantities of FFPE tumors, as in studies of early-stage melanoma. The study describes, for the first time, the optimal strategy for obtaining archival and limited tumor tissue, the characteristics of the nucleic acids co-extracted from a unique cell lysate, and success rate in downstream applications. In addition, our findings provide an estimate of the anticipated attrition that will guide other large multicenter research and consortia